hereinafter , exemplary embodiments of the present invention will be described in detail . however , the exemplary embodiments below merely illustrate the present invention , and the present invention is not limited to the embodiments . measuring amount of sirt1 expression after treatment of lps and interferon to macrophage originated from mouse marrow femur and tibia marrow cells of c57bl / 6 mouse have been differentiated in culture solution containing m - csf ( 10 ng / ml ), and then have been used as mouse macrophage . lps ( 0 , 100 , 500 , 1000 ng / ml ) and interferon beta ( 0 , 100 , 200 , 500 units / ml ) have been injected to the macrophage by concentrations , and the sirt1 expression amount has been compared by western blot . further , the sirt1 protein expression amount when lps has been injected along with ifn - β blocking antibody has been measured . as illustrated in fig1 , when lps has been injected to the macrophage originated from the mouse marrow by 100 ng / ml , the sirt protein expression has increased most , and when 500 ng / ml and 1000 ng / ml of lps has been used , the sirt1 protein expression has rather decreased . further , when interferon beta has been used by concentrations , the sirt1 expression has most significantly increased when 100 units / ml has been used . further , the sirt1 expression increased by lps decreased again by injecting tfn - β blocking antibody together . hence , it can be known that the secretion of the sirt1 , which has been increased by lps , is performed through the interferon beta , and through which the interferon beta induces the expression of sirt1 ( b ). influence of adenovirus - sirt1 and interferon beta on the amount of secretion of pro - inflammatory and anti - inflammatory cytokines after infecting the macrophage with the adenovirus - sirt1 by 10 , 000 moi ( multiplicity of infection ), lps 100 ng / ml has been injected for 24 hours . further , lps 100 ng / ml has been used along with interferon beta 100 units / ml for 24 hours , and then the amount of secretion of pro - inflammatory and anti - inflammatory cytokines of the cell culture medium has been measured by elisa . the experiment has been performed three times , and the result has been expressed by the average ± standard deviation . as shown in fig2 , with respect to the amount of the pro - inflammatory cytokines , which has been increased by the lps treatment , il - 6 has been decreased by 40 % and 54 %, respectively , and tnf - α has been decreased by 22 % and 29 %, respectively , by the pre - treatment of adenovirus - sirt1 and interferon beta . further , it has been found that mop - 1 , which is another pro - inflammatory cytokine , which is increased by the lps treatment , has , slightly decreases by the adenovirus - sirt1 and interferon beta . in contrast , it has been found that the amount of the il - 10 , which is the anti - inflammatory cytokine , has increased by 2 . 8 times and 4 . 7 times , respectively . hence , it is understood that the treatment by the interferon beta , which is the cytokine that promotes the expression of sirt1 , may inhibit the excessive inflammatory response by the lps . analysis of survival rate of mouse after injecting lps after pre - treatment of sirt1 or interferon beta to mouse adenovirus - lacz , which is control gene delivery system , and adenovirus - sirt1 , which is the sirt1 gene delivery system , are injected into the mouse tail vein by 3 × 10 8 pfu ( plaque forming unit ), and lps 15 - 20 mg / kg after 48 hours . then the survival rate of the mouse has been observed for 10 days . further , interferon beta 1000 units or the same amount of salt solution per 20 g of the mouse weight is injected into the mouse tail vein , and lps 15 - 20 mg / kg has been injected after 30 minutes . then the survival rate of the mouse has been observed for 10 days . as shown in fig3 , when the lps is injected to the mouse which has been pre - injected with the adenovirus - sirt1 , the survival rate of the mouse after 10 days is and thus the survival rate has been significantly higher than the survival rate 20 % of the control group , ane mouse , to which the adenovirus - lacz has been injected . further , the survival rate of the mouse , into which the lps has been injected after the injection of the interferon beta , was 70 %, which was significantly higher than the survival rate 30 % of the control group , the mouse , into which the salt solution has been injected . the result shows a significant difference even by the kaplan - meier survival statistical analysis ( p & lt ; 0 . 05 ). hence , the interferon beta , which is a substance that induces the sirt1 expression , significantly reduces the mortality of the mouse by the lps treatment by inhibiting the excessive inflammatory response by lps . analysis of survival rate of mouse at the time of treatment of adenovirus - dominant - negative sirt1 adenovirus - dominant - negative sirt1 , which the gene delivery system for blocking the function of the intrinsic sirt1 , ( adenovirus for inducing mutant protein that has changed histidine no . 355 into tyrosine ), is injected into the mouse tail vein by 3 × 10 3 pfu , and after 48 hours , interferon beta 1000 units per 20 g of the mouse weight is injected into the mouse tail vein . after 30 minutes , lps 15 ˜ 20 mg / kg is injected , and the survival rate of the mouse is observed for 10 days . as shown in fig4 , in the case in which adenovirus - dominant - negative sirt1 is pre - injected for 48 hours , interferon beta is injected and then lps is infected into the mouse , the survival rate 50 % has been observed after 10 days . this is a result similar to the survival rate 50 % of the control group , the mouse into which the salt solution has been injected , and through which the interferon beta , which is the material for inducing the sirt1 expression , significantly reduces the mortality of the mouse by lps . analysis of survival rate according to sirt1 and interferon beta treatment in a mouse sepsis model in a mouse sepsis model , which is induced through cecal ligation and puncture ( clp ) surgery , the following experiment has been performed to check the survival rate changed according to the injection of sirt1 and interferon beta . adenovirus - lacz or adenovirus - sirt1 has been injected into the mouse tail vein 3 × 10 8 pfu . after 24 hours , the anesthetic is injected into the abdominal cavity , and the sepsis has been caused through clp . that is , after the center of the abdomen of the mouse is cut , the appendix is exposed to the outside so that the end of the ileocecal valve is ligated by the silk suture , two holes are made using a needle , and then a certain amount of fecal materials are discharged . the appendix as well as fecal materials has been inserted again into the abdomen , then the abdomen has been stitched , and then a physiological salt solution has been injected through a hypodermic injection . after two hours of slp operation , interferon beta 1000 units or the same amount of salt solution per 20 g of the mouse weight have been injected into the mouse tail vein . as shown in fig5 , the sepsis is induced to the mouse into which the adenovirus - sirt1 has been injected in advance , and the survival rate of the mouse after 10 days was 60 %. this is a significantly high survival rate of 0 % of the control group , mouse into which the adenovirus - lacz has been injected in advance . further , in the case of the experimental group in which interferon beta has been injected into the sepsis - induced mouse , the survival rate was 76 , but in the case of the control group , the mouse into which the salt solution has been injected , the survival rate was 0 %. the result shows a significant difference even by kaplan - meier survival statistical analysis ( p & lt ; 0 . 05 ). hence , the interferon beta , which induces the expression of sirt1 , significantly reduces the mortality of the mouse due to the sepsis , and thus may be utilized in preventing or treating the sepsis or septic shock . substances for a composition of the present invention are illustrated below . the above materials are mixed and are then filled in an airtight container so as to make powder . after mixing the above materials , pills are manufactured according to a general pill manufacturing method . after mixing the above materials , capsules are prepared in gelatin capsules according to a general capsule manufacturing method . the foods containing sirt1 expression inducing materials of the present invention have been made as follows . spice for cooking for health improvement has been made as 20 to 95 weight % of sirt1expression inducing materials . 0 . 2 to 1 . 0 weight % of sirt1 expression inducing materials has been added to tomato ketchup or sauce so as to make tomato ketchup or sauce for health improvement . 0 . 5 to 5 . 0 weight % of sir9 expression inducing materials are added to wheat flour , and bread , cake , cookies , crackers and noodles are made using the mixture so as to prepare food for health improvement . 0 . 1 to 5 . 0 weight % of sirt1 expression inducing materials are added to soups and gravies so as to prepare meat processed food , soups of noodles , and gravies for health improvement . 10 weight % of sirt expression . inducing materials is added to the ground beef so as to prepare the ground beef for health improvement . 5 to 10 weight % of sirt1 expression . inducing materials is added to milk , and various diary products such as butter and ice cream are made using the milk . 10 to 15 % of sirt expression inducing materials , 5 to 10 % of sugar , 0 . 05 to 0 . 3 % of citric acid , 0 . 005 to 0 . 02 % of caramel , 0 . 1 to 1 % of vitamin c and 70 to 80 % of refined water are mixed to make syrup . the syrup is sterilized for 20 to 180 seconds at 85 ˜ 98 ° c ., and the syrup is mixed with the cooling water at the ratio of 1 : 4 , then 0 . 5 to 0 . 82 % of carbonic acid gas is injected so as to prepare soda containing sirt1 expression inducing materials . sirt1 expression inducing materials ( solid content 2 . 5 %, 97 . 16 %), jujube extract ( 65 brix , 2 . 67 ), fruit and vegetable extract ( solid content 70 %, 0 . 12 %), vitamin c ( 0 . 02 %), calcium pantothenate ( 0 . 02 ), licorice extract ( solid content 65 %, 0 . 01 %) are mixed , then the mixture is sterilized for a few seconds , and then the mixture is packed . in a small container such as a glass bottle and a plastic bottle so as to make a health drink , 0 . 5 g of sirt1 expression inducing materials is added to 1 . 00 ml of tomato or carrot juice so as to snake a vegetable juice for health improvement . 0 . 1 g of sirt1 expression inducing materials is added to 1 , 000 ml of apple or grape juice so as to make a fruit juice for health improvement .
the present invention relates to a composition containing an inducer of sirt1 expression for preventing or treating sepsis or septic shock . the inducer of sirt1 expression can remarkably reduce the mortality caused by sepsis or septic shock by reducing pro - inflammatory cytokines and increasing anti - inflammatory cytokines . therefore , the inducer of sirt1 expression is useful for preventing or treating sepsis or septic shock .